U-ONCY

Q:ONCY - ONCOLYTICS BIOTECH INC - http://www.oncolyticsbiotech.com

03:21:01 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
ONCY - Q	0.1	1.05	·	1.19	0.1	1.08	+0.04	3.8	302.7	312	436	1.03 1.1201 1.03	3.3942 0.883	Apr 25	Apr 25	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market: Nasdaq -- Bid Tick: Down -- UPC Restricted: No

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Options · Portfolio

Recent Trades - Last 10 of 436

More trades...

Time ET	Ex	Price	Change	Volume
18:08:15	Q	1.10	0.04	454
17:43:40	Q	1.10	0.04	90
16:40:41	Q	1.06		13
16:20:43	Q	1.13	0.07	20
16:10:53	Q	1.13	0.07	50
16:00:00	Q	1.08	0.02	88
16:00:00	Q	1.08	0.02	14
16:00:00	Q	1.08	0.02	12
15:59:57	Q	1.09	0.04	100
15:59:57	Q	1.09	0.03	1

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2024-04-25 07:00	U:ONCY	News Release200	Oncolytics Biotech(TM) Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting
2024-04-11 07:00	U:ONCY	News Release200	Oncolytics Biotech(TM) Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
2024-04-02 07:00	U:ONCY	News Release200	Oncolytics Biotech(TM) to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference

Date ET

Symbol

Type

Headline

2024-04-25 07:00

U:ONCY

News Release

Oncolytics Biotech(TM) Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting

2024-04-11 07:00

U:ONCY

News Release

Oncolytics Biotech(TM) Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA

2024-04-02 07:00

U:ONCY

News Release

Oncolytics Biotech(TM) to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference